tavaborole (kerydin) Report issue

Small molecule Approved FDA First in Class
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tavaborole is a boron-based pharmaceutical agent indicated for the topical treatment of toenail onychomycosis, a fungal infection of the nail and nail bed due to Trichophyton rubrum or Trichophyton mentagrophytes infection. Tavaborole acts by inhibiting an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS) - Leucyl-tRNA synthetase. Leucyl-tRNA synthetase is an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). Tavaborole’s low molecular weight (approximately half of most antifungals, such as terbinafine and efinaconazole) permits optimal nail plate penetration, superior to that of existing topical antifungal medications.   NCATS

Chemistry

  • SMILES: OB1OCC2=C1C=CC(F)=C2
  • InChIKey: LFQDNHWZDQTITF-UHFFFAOYSA-N
  • Mol. Mass: 151.931
  • ALogP: Missing data
  • ChEMBL Molecule:
    tavaborole  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$145.0342 - $1071.6100
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole | 5-fluoro-2,1-benzoxaborol-1(3h)-ol | an2690 | an 2690 | an-2690 | kerydin | tavaborole

Organizations (14)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Onychomycosis

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Onychomycosis ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue